ClinicalTrials.gg
WithdrawnNCT03227783Updated Nov 10, 2026

The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in PD

An interventional study of transcranial direct current stimulation (tDCS) in Parkinson's Disease, sponsored by Inje University. Withdrawn at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Inje University · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
We cannot enroll the participants
Updated Nov 10, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Parkinson Disease with a site in Korea, Republic of — 13 open to participants now, 15 under way, 1 of them phase 3. Parkinson Disease · Korea, Republic of.

Enrollment
67th of 67
0 · median 60
Started
2019
the only one that year
No phase
28 of 76
6 open now
Registered
41st of 76
by date
Lead sponsor
2 of 76
Inje University

Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, this one is the 67th largest by enrollment of the 67 interventional ones that give a count, is the only one that started in 2019, is one of 28 with no phase, and was the 41st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

13 of the 76 studies in Parkinson Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Parkinson Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Depression is common in Parkinson's disease (PD), but the effective treatment is not established yet. tDCS is a non-invasive brain stimulation to modulate brain function. The tDCS on the depression in general population were already conducted, but not in PD. This study is to know whether transcranial direct current stimulation (tDCS) is effective for the treatment of depression in PD. Participant will be asked to visit three consecutive days for the non-invasive stimulation.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • UK Parkinson's disease brain bank criteria
  • more than 19 years old
  • Able to provide consent for the protocol
  • Depression (based on criteria)

Exclusion criteria

Exclusion Criteria:

  • Dementia
  • Unpredictable symptom fluctuations
  • to tDCS (i) irritations, cuts, lesions in the brain (ii) any preexisting unstable medical conditions, or conditions that may increase the risk of stimulation such as uncontrolled epilepsy (iii) history of severe cranial trauma with alteration of the cranial anatomy or metallic intracranial implants (iv) history of seizure
  • Subjects without the capacity to give
  • If participation in the study would, in the opinion of the investigators, cause undue risk or stress for reasons such as excessive fatigue, general frailty, or excessive apprehension
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Real tDCS

    * Constant weak electric currents through scalp via two electrodes will be delivered. * Current intensity: 2mA, 20min/day

    Device: transcranial direct current stimulation (tDCS)

  • Sham comparator
    Sham tDCS

    * a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects * Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)

    Device: transcranial direct current stimulation (tDCS)

Interventions

  • Devicetranscranial direct current stimulation (tDCS)

    tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.

06

What researchers measure

Primary outcomes

  1. BDI score

    The changes of Beck depression inventory after tDCS

    Time frame: (1) before the1st visit (within one month) (2) right after the 3rd tDCS (3) within one months after the 3rd tDCS

Secondary outcomes

  1. HDRS score

    The changes of Hamilton Depression Rating Scale after tDCS

    Time frame: (1) before the 1st visit (within one month) (2) right after 3rd tDCS, within 24 hours (3) within one months after the 3rd tDCS

  2. MADRS score

    The changes of Mongomery-Asberg Depression Rating Scale after tDCS

    Time frame: (1) before the 1st visit (within one month) (2) right after the 3rd tDCS, within 24 hours (3) within one months after 3rd tDCS

  3. resting state functional MRI

    The changes of resting state functional MRI after tDCS

    Time frame: (1) before the 1st visit (within one month) (2) after the 3rd tDCS, within 24 hours (on the same day as the 3rd tDCS)

07

Study locations

1 site
  • Inje university, Busan Paik Hospital
    Busan, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2019; primary completion for Dec 2020, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2017
First posted
Jul 24, 2017
StartEst.
Feb 2019
Primary completionEst.
Dec 2020
CompletionEst.
Dec 2021
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Withdrawn We cannot enroll the participants
changed Nov 10, 2026
Enrollment
26 (estimated)→0 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Status unknown→Withdrawn
    Why stopped We cannot enroll the participants
    Enrollment 26 (estimated)→0 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03227783
Lead sponsor
Inje University
Responsible party
Sangjin Kim (Professor, Inje University) — Principal investigator
First posted
Jul 24, 2017
Start date
Feb 2019 (estimated)
Primary completion
Dec 2020 (estimated)
Completion
Dec 2021 (estimated)
Last update
Nov 10, 2026

Study contacts

Sang Jin Kim, MD, PhD
principal investigator · Inje University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion